QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
Log in
NASDAQ:PLRX

Pliant Therapeutics Stock Forecast, Price & News

$34.35
+2.84 (+9.01 %)
(As of 03/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$31.59
Now: $34.35
$37.75
50-Day Range
$24.61
MA: $30.69
$40.06
52-Week Range
$19.42
Now: $34.35
$43.92
Volume150,634 shs
Average Volume132,273 shs
Market Capitalization$1.22 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avÃ6 and avÃ1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, small-molecule selective inhibitor of avÃ1, which is Phase 1 clinical trials for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.

Headlines

Creating More Affordable Homes for Families in Red Lake
February 17, 2021 |  finance.yahoo.com
Pliant Therapeutics Inc
December 21, 2020 |  reuters.com
Is PLRX A Good Stock To Buy Now?
December 11, 2020 |  finance.yahoo.com
Pliant Therapeutics Inc.
September 25, 2020 |  marketwatch.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PLRX
CUSIPN/A
CIKN/A
Phone650-481-6770
Employees70
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$57.05 million

Profitability

Net Income$-630,000.00

Miscellaneous

Market Cap$1.22 billion
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.91 out of 5 stars

Medical Sector

225th out of 1,971 stocks

Pharmaceutical Preparations Industry

103rd out of 772 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$34.35
+2.84 (+9.01 %)
(As of 03/8/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PLRX News and Ratings via Email

Sign-up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pliant Therapeutics (NASDAQ:PLRX) Frequently Asked Questions

Is Pliant Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pliant Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Pliant Therapeutics stock.
View analyst ratings for Pliant Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Pliant Therapeutics?

Wall Street analysts have given Pliant Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pliant Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Pliant Therapeutics' next earnings date?

Pliant Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Pliant Therapeutics
.

How were Pliant Therapeutics' earnings last quarter?

Pliant Therapeutics, Inc. (NASDAQ:PLRX) released its earnings results on Tuesday, November, 10th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.85) by $0.38. The company earned $4.81 million during the quarter. Pliant Therapeutics had a trailing twelve-month return on equity of 16.55% and a net margin of 20.83%.
View Pliant Therapeutics' earnings history
.

What price target have analysts set for PLRX?

4 brokers have issued 12 month price targets for Pliant Therapeutics' stock. Their forecasts range from $40.00 to $50.00. On average, they anticipate Pliant Therapeutics' share price to reach $43.33 in the next year. This suggests a possible upside of 26.2% from the stock's current price.
View analysts' price targets for Pliant Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Pliant Therapeutics' key executives?

Pliant Therapeutics' management team includes the following people:
  • Prof. Bernard Coulie M.B.A., Ph.D., M.D., MBA, Pres, CEO & Director (Age 55, Pay $699.21k)
  • Dr. Keith Lamont Cummings M.B.A., M.D., Chief Financial Officer (Age 44, Pay $725.6k)
  • Mr. Johannes P. Hull, Chief Bus. Officer (Age 46, Pay $577.71k)
  • Dr. Rik Derynck, Scientific Founder & Member of Scientific Advisory Board
  • Mr. Dean Sheppard M.D., Scientific Founder & Member of Scientific Advisory Board
  • Mr. Bill DeGrado Ph.D., Scientific Founder & Member of Scientific Advisory Board
  • Mr. Hal Chapman M.D., Scientific Founder & Member of Scientific Advisory Board
  • Mr. Craig D. Muir, Interim Chief Technology Officer
  • Mr. Christopher S. Keenan, VP of Investor Relations & Corp. Communications
  • Mr. Mike Ouimette, Gen. Counsel & Corp. Sec.

Who are some of Pliant Therapeutics' key competitors?

What other stocks do shareholders of Pliant Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pliant Therapeutics investors own include Pfizer (PFE), Ampio Pharmaceuticals (AMPE), CrowdStrike (CRWD), Trevena (TRVN), AbbVie (ABBV), Abbott Laboratories (ABT), Archer-Daniels-Midland (ADM), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN).

When did Pliant Therapeutics IPO?

(PLRX) raised $90 million in an IPO on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler served as the underwriters for the IPO and Needham & Company was co-manager.

What is Pliant Therapeutics' stock symbol?

Pliant Therapeutics trades on the NASDAQ under the ticker symbol "PLRX."

Who are Pliant Therapeutics' major shareholders?

Pliant Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include CHI Advisors LLC (6.64%), BlackRock Inc. (2.41%), Lord Abbett & CO. LLC (0.53%), Bank of New York Mellon Corp (0.27%), Charles Schwab Investment Management Inc. (0.18%) and Swiss National Bank (0.07%). Company insiders that own Pliant Therapeutics stock include Bernard Coulie, Eric Lefebvre and Keith Lamont Cummings.
View institutional ownership trends for Pliant Therapeutics
.

Which institutional investors are selling Pliant Therapeutics stock?

PLRX stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC. Company insiders that have sold Pliant Therapeutics company stock in the last year include Bernard Coulie, Eric Lefebvre, and Keith Lamont Cummings.
View insider buying and selling activity for Pliant Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Pliant Therapeutics stock?

PLRX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Swiss National Bank, State of Wisconsin Investment Board, Virtus ETF Advisers LLC, Rhumbline Advisers, Hsbc Holdings PLC, Bank of New York Mellon Corp, and Wells Fargo & Company MN.
View insider buying and selling activity for Pliant Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Pliant Therapeutics?

Shares of PLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pliant Therapeutics' stock price today?

One share of PLRX stock can currently be purchased for approximately $34.35.

How much money does Pliant Therapeutics make?

Pliant Therapeutics has a market capitalization of $1.22 billion and generates $57.05 million in revenue each year.

How many employees does Pliant Therapeutics have?

Pliant Therapeutics employs 70 workers across the globe.

What is Pliant Therapeutics' official website?

The official website for Pliant Therapeutics is pliantrx.com.

Where are Pliant Therapeutics' headquarters?

Pliant Therapeutics is headquartered at 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Pliant Therapeutics?

Pliant Therapeutics' mailing address is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-481-6770 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.